Steris Plc (STE) has had a varying performance in stock market in the recent past, with periods of underperformance compared to competitors and other instances of outperforming the market. Its market price has hovered around the
$246.00 target price set by analysts. Solid Q2 numbers and upbeat Q1 earnings reports that exceed estimates are backing a positive thesis. Major stakeholders including
Daymark Wealth Partners LLC and AQR Capital Management LLC have increased their stakes while others like Clearbridge Investments LLC and APG Asset Management N.V. have reduced theirs. Strategically, Steris has made some significant moves, such as the divestiture of its Dental unit, acquisition of Surgical instrumentation but is seen as overvalued by certain analysts. The company also plans to sell its renal care business for
$196 million, focusing on debt reduction. It’s international revenue trends, potential CEO pay rise and increased dividends for shareholders point to a positive outlook for the company. However, Steris also recently announced its restructuring plan that will result in layoffs.
Steris Plc STE News Analytics from Mon, 30 Jul 2018 10:21:44 GMT to Thu, 10 Oct 2024 17:36:53 GMT -
Rating 5
- Innovation 3
- Information 7
- Rumor -2
